Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on May 13, 2025

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101’s potential to address critical gaps in SUDEP …

Affimed Announces Filing for the Opening of Insolvency Proceedings
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for …

OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the …

PBGH Announces Jumbo Employers’ Top 5 Health Care Priorities
Oakland, California, May 13, 2025 (GLOBE NEWSWIRE) -- Purchaser Business Group on Health (PBGH), a nonprofit coalition representing 40 private employers and public entities across the U.S., announced today the results of its member survey on top health …

VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the …

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting …

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury
DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced …

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate …

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a …

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, …

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will …

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 …

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline …

Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the …

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, …

Ernst & Young LLP Names Brian Webster of Kestra Medical Technologies as an Entrepreneur Of The Year® 2025 Mountain West Award Finalist
Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future KIRKLAND, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Ernst …

Reviva to Participate in the A.G.P. Healthcare Company Showcase
CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central …

Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. …

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend …

Reflect Scientific Secures Patents for Data Center Cooling with Cryogenic Innovation
OREM, Utah, May 13, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leader in cryogenic technology, today announced a U.S. Patent for its innovative system to cool computer rooms using cryogenic methods. This development addresses the …